News
SRDX
41.44
-0.26%
-0.11
Weekly Report: what happened at SRDX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at SRDX last week (0708-0712)?
Weekly Report · 07/15 09:00
Weekly Report: what happened at SRDX last week (0701-0705)?
Weekly Report · 07/08 09:00
Weekly Report: what happened at SRDX last week (0624-0628)?
Weekly Report · 07/01 09:00
Weekly Report: what happened at SRDX last week (0617-0621)?
Weekly Report · 06/24 09:00
Press Release: Kuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law Firm
Dow Jones · 06/17 12:08
Weekly Report: what happened at SRDX last week (0610-0614)?
Weekly Report · 06/17 09:00
Surmodics (SRDX) Inks Group Purchasing Agreement With Premier
NASDAQ · 06/11 14:38
Surmodics secures thrombectomy products agreement with Premier
Healthcare Surmodics secures thrombectomy products agreement with Premier. Premier is a healthcare improvement company, uniting an alliance of more than 4,350 U.S. Hospitals. Sur modics awarded a group purchasing agreement for throm bectomy products with Premier, effective June 1, 2024.
Seeking Alpha · 06/10 12:08
Surmodics Secures A Group Purchasing Agreement For Thrombectomy Products With Premier, Inc. ; No Terms Disclosed
Benzinga · 06/10 11:02
SURMODICS AWARDED THROMBECTOMY PRODUCTS AGREEMENT WITH PREMIER, INC.
Reuters · 06/10 11:00
Weekly Report: what happened at SRDX last week (0603-0607)?
Weekly Report · 06/10 09:00
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
Surmodics has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Premier is a leading alliance of more than 4,350 U.S. Hospitals and 300,000 other providers. The new agreement allows Premier members to take advantage of special pricing and terms for Surmodics systems. Surmodic is a provider of medical device and in vitro diagnostic technologies.
Barchart · 06/10 06:00
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Simply Wall St · 06/06 11:23
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate SRCL, MRO, SRDX, ATRI
Barchart · 06/03 18:54
Weekly Report: what happened at SRDX last week (0527-0531)?
Weekly Report · 06/03 09:00
Assessing Surmodics: Insights From 5 Financial Analysts
Surmodics is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company has been analyzed by 5 analysts in the last three months. Surmodics has a 12-month average price target of $. The firm has a positive revenue growth rate of approximately 10%. The company's market capitalization is below industry averages.
Benzinga · 05/30 17:01
Surmodics Cut to Market Perform From Outperform by Barrington Research
Dow Jones · 05/30 14:15
Barrington Research Downgrades Surmodics to Market Perform
Benzinga · 05/30 14:06
SurModics (SRDX) was downgraded to a Hold Rating at Barrington
TipRanks · 05/30 13:15
More
Webull provides a variety of real-time SRDX stock news. You can receive the latest news about Surmodics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRDX
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.